Pharmaceutical Technology

FEBRUARY 3, 2023

Researchers have relentlessly worked through the barriers to create lifechanging treatments for patients in need. “As For example, researchers have developed a two-plasmid cotransfection system. Moving the viral vector field closer to the monoclonal antibody field is really what we see as the way forward.”

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Looking forward .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

SEPTEMBER 28, 2022

PerkinElmer has launched the Cellaca PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity. . ” . . ” .

Gene Therapy 52

Gene Therapy Manufacturing Gene Reagent 52

Drug Discovery World

FEBRUARY 15, 2023

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. This is an exciting field of cancer research which involves harnessing the body’s own immune system to target cancerous cells.

Research 52

Research In-Vitro In-Vivo Development 52

XTalks

APRIL 22, 2022

Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

Drug Discovery World

OCTOBER 21, 2022

Flow cytometry is a well-established analytical technique that has been supporting reliable diagnostics and groundbreaking research for decades. A major breakthrough in the technology was the development of biologically active fluorescent reagents that could be detected by the instruments. Overview, evolution, trends .

Reagent 52

Reagent Antibody Drugs Protein 52

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

FEBRUARY 27, 2023

The system features high-throughput fast dual detectors, enabling researchers to screen millions of samples with the increased accuracy, speed and sensitivity. This enables researchers to perform a wide range of assays for different applications within one instrument.

Drugs 52

Drugs Life Science Protein Scientist 52

Drug Discovery World

JULY 18, 2023

Years of development and fast-paced research have continued to unlock its potential, expanding how CRISPR can be used to treat, detect, and prevent common diseases such as cancer and Covid-19. Another promising approach consists of conjugating antibodies, such as an anti-CD38, to the LNPs for targeted delivery into specific tissues.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

OCTOBER 20, 2022

Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done. For imaging mass cytometry, heavy metal-conjugated antibodies are added simultaneously to a tissue section adhered to a slide.

Antibody 52

Antibody In-Vivo Life Science Development 52